Search

Your search keyword '"Cerny, Jan"' showing total 165 results
Start Over Author "Cerny, Jan" Publication Year Range Last 3 years

Refine your results

more »

more »

more »

more »
165 results on '"Cerny, Jan"'

1. Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities.

Author

Khera, Nandita, Ailawadhi, Sikander, Brazauskas, Ruta, Patel, Jinalben, Jacobs, Benjamin, Ustun, Celalettin, Ballen, Karen, Abid, Muhammad, Diaz Perez, Miguel, Al-Homsi, A, Hashem, Hasan, Hong, Sanghee, Munker, Reinhold, Schears, Raquel, Lazarus, Hillard, Ciurea, Stefan, Badawy, Sherif, Savani, Bipin, Wirk, Baldeep, LeMaistre, C, Bhatt, Neel, Beitinjaneh, Amer, Aljurf, Mahmoud, Sharma, Akshay, Cerny, Jan, Knight, Jennifer, Kelkar, Amar, Yared, Jean, Kindwall-Keller, Tamila, Winestone, Lena, Steinberg, Amir, Arnold, Staci, Seo, Sachiko, Preussler, Jaime, Hossain, Nasheed, Fingrut, Warren, Agrawal, Vaibhav, Hashmi, Shahrukh, Lehmann, Leslie, Wood, William, Rangarajan, Hemalatha, Saber, Wael, and Hahn, Theresa

Subjects
Humans, Hematopoietic Stem Cell Transplantation, Male, Female, Adult, Middle Aged, Ethnic and Racial Minorities, Adolescent, Child, Aged, Young Adult, Child, Preschool
Abstract

There has been an increase in volume as well as an improvement in overall survival (OS) after hematopoietic cell transplantation (HCT) for hematologic disorders. It is unknown if these changes have affected racial/ethnic minorities equally. In this observational study from the Center for International Blood and Marrow Transplant Research of 79 904 autologous (auto) and 65 662 allogeneic (allo) HCTs, we examined the volume and rates of change of autoHCT and alloHCT over time and trends in OS in 4 racial/ethnic groups: non-Hispanic Whites (NHWs), non-Hispanic African Americans (NHAAs), and Hispanics across 5 2-year cohorts from 2009 to 2018. Rates of change were compared using Poisson model. Adjusted and unadjusted Cox proportional hazards models examined trends in mortality in the 4 racial/ethnic groups over 5 study time periods. The rates of increase in volume were significantly higher for Hispanics and NHAAs vs NHW for both autoHCT and alloHCT. Adjusted overall mortality after autoHCT was comparable across all racial/ethnic groups. NHAA adults (hazard ratio [HR] 1.13; 95% confidence interval [CI] 1.04-1.22; P = .004) and pediatric patients (HR 1.62; 95% CI 1.3-2.03; P < .001) had a higher risk of mortality after alloHCT than NHWs. Improvement in OS over time was seen in all 4 groups after both autoHCT and alloHCT. Our study shows the rate of change for the use of autoHCT and alloHCT is higher in NHAAs and Hispanics than in NHWs. Survival after autoHCT and alloHCT improved over time; however, NHAAs have worse OS after alloHCT, which has persisted. Continued efforts are needed to mitigate disparities for patients requiring alloHCT.

Published
2024

2. Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis

Author

Wang, Trent P., Ahn, Kwang W., Shadman, Mazyar, Kaur, Manmeet, Ahmed, Nausheen, Bacher, Ulrike, Cerny, Jan, Chen, Andy, Epperla, Narendranath, Frigault, Matthew, Grover, Natalie, Haverkos, Bradley, Hill, Brian, Hossain, Nasheed, Iqbal, Madiha, Jain, Tania, Krem, Maxwell M., Maakaron, Joseph, Modi, Dipenkumar, Alhaj Moustafa, Muhamad, Riedell, Peter, Savani, Bipin, Sica, R. Alejandro, Sureda, Anna, Wudhikarn, Kitsada, Herrera, Alex F., Sauter, Craig, Hamadani, Mehdi, and Jimenez Jimenez, Antonio

Published
2024
Full Text
View/download PDF

3. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.

Author

Boyiadzis, Michael, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif, Battiwalla, Minoo, Bejanyan, Nelli, Bhatt, Vijaya, Brown, Valerie, Castillo, Paul, Cerny, Jan, Copelan, Edward, Craddock, Charles, Dholaria, Bhagirathbhai, Perez, Miguel, Ebens, Christen, Gale, Robert, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael, Hashmi, Shahrukh, Hildebrandt, Gerhard, Iqbal, Madiha, Jamy, Omer, Kharfan-Dabaja, Mohamed, Khera, Nandita, Lazarus, Hillard, Lin, Richard, Modi, Dipenkumar, Nathan, Sunita, Nishihori, Taiga, Patel, Sagar, Pawarode, Attaphol, Saber, Wael, Sharma, Akshay, Solh, Melhem, Wagner, John, Wang, Trent, Williams, Kirsten, Wirk, Baldeep, Zeidan, Amer, Hourigan, Christopher, Litzow, Mark, Kebriaei, Partow, de Lima, Marcos, Page, Kristin, Weisdorf, Daniel, and Winestone, Lena

Subjects
Adult, Humans, Transplantation, Homologous, Transplantation Conditioning, Neoplasm Recurrence, Local, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Retrospective Studies
Abstract

We investigated the impact of the number of induction/consolidation cycles on outcomes of 3113 adult AML patients who received allogeneic hematopoietic cell transplantation (allo-HCT) between 2008 and 2019. Patients received allo-HCT using myeloablative (MAC) or reduced-intensity (RIC) conditioning in first complete remission (CR) or with primary induction failure (PIF). Patients who received MAC allo-HCT in CR after 1 induction cycle had 1.3-fold better overall survival (OS) than 2 cycles to CR and 1.47-fold better than ≥3 cycles. OS after CR in 2 or ≥3 cycles was similar. Relapse risk was 1.65-fold greater in patients receiving ≥3 cycles to achieve CR. After RIC allo-HCT, the number of induction cycles to CR did not affect OS. Compared to CR in 1 cycle, relapse risk was 1.24-1.41-fold greater in patients receiving 2 or ≥3 cycles. For patients receiving only 1 cycle to CR, consolidation therapy prior to MAC allo-HCT was associated with improved OS vs. no consolidation therapy. Detectable MRD at the time of MAC allo-HCT did not impact outcomes while detectable MRD preceding RIC allo-HCT was associated with an increased risk of relapse. For allo-HCT in PIF, OS was significantly worse than allo-HCT in CR after 1-3 cycles.

Published
2023

7. Information Literacy in International Masters Students: A Competitive and Business Intelligence Course Perspective

Author

Cerny, Jan and Potancok, Martin

Abstract

This original research is directed towards the information literacy of international master's students, focusing on the evaluation of their information-seeking behaviour during competitive and business intelligence processes, together with the subsequent verification methods they use once the desired information is found. During this research, 207 students received a test with questions related to business information literacy, with either one or more options or free-text answers. The results showed a significant lack of information literacy in the use of information sources, including knowledge about their existence and consequent search habits, but they did at least also show a fundamental awareness of verification methods. The students also demonstrated awareness of the significance of data visualisation needs when reporting the contexts found in business intelligence process data.

Published
2023
Full Text
View/download PDF

9. Number of HLA-Mismatched Eplets Is Not Associated with Major Outcomes in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: A Center for International Blood and Marrow Transplant Research Study.

Author

Zou, Jun, Wang, Tao, He, Meilun, Bolon, Yung-Tsi, Gadalla, Shahinaz, Marsh, Steven, Kuxhausen, Michelle, Gale, Robert, Sharma, Akshay, Assal, Amer, Prestidge, Tim, Aljurf, Mahmoud, Cerny, Jan, Paczesny, Sophie, Spellman, Stephen, Lee, Stephanie, and Ciurea, Stefan

Subjects
Allogeneic transplantation, HLA mismatching, Haploidentical donors, Cyclophosphamide, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Recurrence, Transplantation, Haploidentical
Abstract

The number of haploidentical hematopoietic stem cell transplantations (haplo-HSCT) performed has increased substantially in recent years. Previous single-center studies using in silico algorithms to quantitively measure HLA disparity have shown an association of the number of HLA molecular mismatches with relapse protection and/or increased risk of acute graft-versus-host disease (GVHD) in haplo-HSCT. However, inconsistent results from small studies have made it difficult to understand the full clinical impact of molecular mismatch in haplo-HSCT. In this study, we investigated the potential of the HLA class I and II mismatched eplet (ME) score measured by HLAMatchmaker, as well as ME load at a specific locus to predict outcomes in a registry-based cohort of haplo-HSCT recipients. We analyzed data from 1287 patients who underwent their first haplo-HSCT for acute lymphoblastic leukemia, acute myelogenous leukemia, or myelodysplastic syndrome between 2013 and 2017, as entered in the Center for International Blood and Marrow Transplant Research database. ME load at each HLA locus and total class I and II were scored using the HLAMatchmaker module incorporated in HLA Fusion software v4.3, which identifies predicted eplets based on the crystalized HLA molecule models and identifies ME by comparing donor and recipient eplets. In the study cohort, ME scores derived from total HLA class I or class II loci or individual HLA loci were not associated with overall survival, disease-free survival, nonrelapse mortality, relapse, acute GVHD, or chronic GVHD (P < .01). An unexpected strong association was identified between total class II ME load in the GVH direction and slower neutrophil engraftment (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.75 to 0.91; P < .0001) and platelet engraftment (HR, 0.80; 95% CI, 0.72 to 0.88; P < .0001). This was likely attributable to ME load at the HLA-DRB1 locus, which was similarly associated with slower neutrophil engraftment (HR, 0.82; 95% CI, 0.73 to 0.92; P = .001) and slower platelet engraftment (HR, 0.76; 95% CI, 0.70 to 0.84; P < .0001). Additional analyses suggested that this effect is attributable to a match versus a mismatch in the graft-versus-host direction and not to ME load, as a dose effect was not identified. These findings contradict those of previous relatively small studies reporting an association between ME load, as quantified by HLAMatchmaker, and haplo-HSCT outcomes. This study failed to demonstrate the predictive value of ME from HLA molecules for major clinical outcomes, and other molecular mismatch algorithms in haplo-HSCT settings should be tested.

Published
2022

10. Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Author

Wieduwilt, Matthew J, Metheny, Leland, Zhang, Mei-Jie, Wang, Hai-Lin, Estrada-Merly, Noel, Marks, David I, Al-Homsi, A Samar, Muffly, Lori, Chao, Nelson J, Rizzieri, David, Gale, Robert Peter, Gadalla, Shahinaz M, Cairo, Mitchell S, Mussetti, Alberto, Gore, Steven D, Bhatt, Vijaya Raj, Patel, Sagar S, Michelis, Fotios V, Inamoto, Yoshihiro, Badawy, Sherif M, Copelan, Edward, Palmisiano, Neil, Kharfan-Dabaja, Mohamed A, Lazarus, Hillard M, Ganguly, Siddhartha, Bredeson, Christopher N, Perez, Miguel Angel Diaz, Cassaday, Ryan, Savani, Bipin N, Ballen, Karen Kuhn, Martino, Rodrigo, Wirk, Baldeep, Bacher, Ulrike, Aljurf, Mahmoud, Bashey, Asad, Murthy, Hemant S, Yared, Jean A, Aldoss, Ibrahim, Farhadfar, Nosha, Liu, Hongtao, Abdel-Azim, Hisham, Waller, Edmund K, Solh, Melhem, Seftel, Matthew, van der Poel, Marjolein WM, Grunwald, Michael Richard, Liesveld, Jane L, Kamble, Rammurti T, McGuirk, Joseph P, Munker, Reinhold, Cahn, Jean-Yves, Lee, Jong Wook, Freytes, Cesar O, Krem, Maxwell, Winestone, Lena E, Gergis, Usama, Nathan, Sunita, Olsson, Richard F, Verdonck, Leo F, Sharma, Akshay, Ringden, Olle, Friend, Brian D, Cerny, Jan, Choe, Hannah K, Chhabra, Saurabh, Nishihori, Taiga, Seo, Sachiko, George, Biju, Baxter-Lowe, Lee Ann, Hildebrandt, Gerhard C, de Lima, Marcos, Litzow, Mark R, Kebriaei, Partow, Hourigan, Christopher S, Abid, Muhammad Bilal, Weisdorf, Daniel J, and Saber, Wael

Subjects
Rare Diseases, Cancer, Pediatric, Pediatric Cancer, Stem Cell Research - Nonembryonic - Human, Orphan Drug, Hematology, Stem Cell Research, Transplantation, Good Health and Well Being, Fetal Blood, Hematopoietic Stem Cell Transplantation, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Siblings, Unrelated Donors
Abstract

The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.

Published
2022

11. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.

Author

Menghrajani, Kamal, Gomez-Arteaga, Alexandra, Madero-Marroquin, Rafael, Zhang, Mei-Jie, Bo-Subait, Khalid, Sanchez, Jonathan, Wang, Hai-Lin, Aljurf, Mahmoud, Assal, Amer, Bacher, Vera, Badawy, Sherif, Bejanyan, Nelli, Bhatt, Vijaya, Bredeson, Christopher, Byrne, Michael, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Ciurea, Stefan, DeFilipp, Zachariah, Farhadfar, Nosha, Gadalla, Shahinaz, Gale, Robert, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael, Hashmi, Shahrukh, Hildebrandt, Gerhard, Kanakry, Christopher, Kansagra, Ankit, Khimani, Farhad, Krem, Maxwell, Lazarus, Hillard, Liu, Hongtao, Martino, Rodrigo, Michelis, Fotios, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard, Reshef, Ran, Rizzieri, David, Rowe, Jacob, Savani, Bipin, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Ustun, Celalettin, Verdonck, Leo, Hourigan, Christopher, Sandmaier, Brenda, Litzow, Mark, Kebriaei, Partow, Weisdorf, Daniel, Zhang, Yanming, Tallman, Martin, and Saber, Wael

Subjects
Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Recurrence, Remission Induction
Abstract

Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes in patients with acute myeloid leukemia (AML). We evaluated 8709 patients with AML from the CIBMTR database, and after selection and manual curation of the cytogenetics data, 3779 patients in first complete remission were included in the final analysis: 2384 with intermediate-risk, 969 with adverse-risk, and 426 with KMT2A-rearranged disease. An adjusted multivariable analysis detected an increased risk of relapse for patients with KMT2A-rearranged or adverse-risk AML as compared to those with intermediate-risk disease (hazards ratio [HR], 1.27; P = .01; HR, 1.71; P < .001, respectively). Leukemia-free survival was similar for patients with KMT2A rearrangement or adverse risk (HR, 1.26; P = .002, and HR, 1.47; P < .001), as was overall survival (HR, 1.32; P < .001, and HR, 1.45; P < .001). No differences in outcome were detected when patients were stratified by KMT2A fusion partner. This study is the largest conducted to date on post-HCT outcomes in AML, with manually curated cytogenetics used for risk stratification. Our work demonstrates that risk classification at diagnosis remains predictive of post-HCT outcomes in AML. It also highlights the critical need to develop novel treatment strategies for patients with KMT2A-rearranged and adverse-risk disease.

Published
2022

13. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis

Author

Murthy, Hemant S., Zhang, Mei-Jie, Chen, Karen, Ahmed, Sairah, Deotare, Uday, Ganguly, Siddhartha, Kansagra, Ankit, Michelis, Fotios V., Nishihori, Taiga, Patnaik, Mrinal, Abid, Muhammad Bilal, Aljurf, Mahmoud, Arai, Yasuyuki, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Ballen, Karen, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Brown, Valerie I., Martino, Rodrigo, Cahn, Jean-Yves, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Copelan, Edward, Daly, Andrew, Dholaria, Bhagirathbhai, Diaz Perez, Miguel Angel, Freytes, César O., Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Jamy, Omer, Joseph, Jacinth, Kanakry, Christopher G., Khera, Nandita, Krem, Maxwell M., Kuwatsuka, Yachiyo, Lazarus, Hillard M., Lekakis, Lazaros J., Liu, Hongtao, Modi, Dipenkumar, Munshi, Pashna N., Mussetti, Alberto, Palmisiano, Neil, Patel, Sagar S., Rizzieri, David A., Seo, Sachiko, Shah, Mithun Vinod, Sharma, Akshay, Sohl, Melhm, Solomon, Scott R., Ulrickson, Matthew, Ustun, Celalettin, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Wang, Trent, Wirk, Baldeep, Zeidan, Amer, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Weisdorf, Daniel J., Saber, Wael, and Kharfan-Dabaja, Mohamed A.

Published
2023
Full Text
View/download PDF

17. Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients

Author

Boyiadzis, Michael, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Battiwalla, Minoo, Bejanyan, Nelli, Bhatt, Vijaya Raj, Brown, Valerie I., Castillo, Paul, Cerny, Jan, Copelan, Edward A., Craddock, Charles, Dholaria, Bhagirathbhai, Perez, Miguel Angel Diaz, Ebens, Christen L., Gale, Robert Peter, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Iqbal, Madiha, Jamy, Omer, Kharfan-Dabaja, Mohamed A., Khera, Nandita, Lazarus, Hillard M., Lin, Richard, Modi, Dipenkumar, Nathan, Sunita, Nishihori, Taiga, Patel, Sagar S., Pawarode, Attaphol, Saber, Wael, Sharma, Akshay, Solh, Melhem, Wagner, John L., Wang, Trent, Williams, Kirsten M., Winestone, Lena E., Wirk, Baldeep, Zeidan, Amer, Hourigan, Christopher S., Litzow, Mark, Kebriaei, Partow, de Lima, Marcos, Page, Kristin, and Weisdorf, Daniel J.

Published
2023
Full Text
View/download PDF

18. Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

Author

Levis, M, Hamadani, M, Logan, B, Jones, R, Singh, A, Litzow, M, Wingard, J, Papadopoulos, E, Perl, A, Soiffer, R, Ustun, C, Ueda Oshima, M, Uy, G, Waller, E, Vasu, S, Solh, M, Mishra, A, Muffly, L, Kim, H, Mikesch, J, Najima, Y, Onozawa, M, Thomson, K, Nagler, A, Wei, A, Marcucci, G, Geller, N, Hasabou, N, Delgado, D, Rosales, M, Hill, J, Gill, S, Nuthethi, R, King, D, Wittsack, H, Mendizabal, A, Devine, S, Horowitz, M, Chen, Y, Agura, E, Altman, J, Anagnostopoulos, A, Anand, S, Artz, A, Aulitzky, W, Balderman, S, Ballen, K, Becker, M, Beguin, Y, Berkahn, L, Berneman, Z, Bhatt, V, Bilmon, I, Bonifazi, F, Briggs, A, Bruno, B, Brunstein, C, Byrne, M, Byrne, J, Cabrero, M, Cairoli, R, Carrum, G, Cerny, J, Cheong, J, Ciceri, F, Colorado, M, Cook, R, Couriel, D, Craddock, C, Damon, L, Deol, A, Desbrosses, Y, Di Grazia, C, Di Stasi, A, Dias, A, Dorritie, K, Essell, J, Eto, T, Farag, S, Forcade, E, Frankfurt, O, Fujiwara, S, Fukuda, T, Fukushima, K, Furst, S, Goto, T, Hall, A, Hatta, S, Hicheri, Y, Horwitz, M, Hou, H, How, J, Howard, D, Hsu, W, Huynh, A, Irvine, D, Ishikawa, T, Jamieson, K, Jedrzejczak, W, Jethava, Y, Jimenez, A, Jung, C, Kanda, J, Karakasis, D, Kato, J, Kekre, N, Khera, N, Klein, A, Kobbe, G, Kornblit, B, Kota, V, Lachance, S, Leber, B, Lee, C, Lee, J, Lin, T, Liu, T, Martelli, M, Martinez, C, Matsuoka, K, Mccarty, J, Mendez, L, Michelis, F, Mineishi, S, Mohty, M, Moors, I, Motyckova, G, Mueller, L, Nakamae, H, Nakano, N, Nathan, S, Nicholson, E, Norkin, M, Ogawa, Y, Olesen, G, Oluwole, O, Pantin, J, Paulson, K, Pemberton, L, Perera, T, Piatkowska-Jakubas, B, Poire, X, Protheroe, R, Rambaldi, A, Ritchie, D, Ross, K, Rubio, M, Santarone, S, Sanz Caballer, J, Sawa, M, Schaar, D, Scheid, C, Schriber, J, Seropian, S, Shah, N, Shore, T, Gil, J, Sobecks, R, Socie, G, Sprague, K, Spyridonidis, A, Stelljes, M, Stiff, P, Stuart, R, Tanaka, M, Tandra, A, Tholouli, E, Thomas, X, Tiribelli, M, Tomlinson, B, Tsirigotis, P, Tzachanis, D, Uchida, N, Ueda, M, Valcarcel Ferreiras, D, Wagner, E, Watson, A, Weisdorf, D, Wolschke, C, Wrobel, T, Yakoub-Agha, I, Yamauchi, T, Yared, J, Yeh, S, Yoon, S, Yoshihara, S, Null, N, Levis, Mark J., Hamadani, Mehdi, Logan, Brent, Jones, Richard J., Singh, Anurag K., Litzow, Mark, Wingard, John R., Papadopoulos, Esperanza B., Perl, Alexander E., Soiffer, Robert J., Ustun, Celalettin, Ueda Oshima, Masumi, Uy, Geoffrey L., Waller, Edmund K., Vasu, Sumithra, Solh, Melhem, Mishra, Asmita, Muffly, Lori, Kim, Hee-Je, Mikesch, Jan-Henrik, Najima, Yuho, Onozawa, Masahiro, Thomson, Kirsty, Nagler, Arnon, Wei, Andrew H., Marcucci, Guido, Geller, Nancy L., Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason, Gill, Stanley C., Nuthethi, Rishita, King, Denise, Wittsack, Heather, Mendizabal, Adam, Devine, Steven M., Horowitz, Mary M., Chen, Yi-Bin, Agura, Ed, Altman, Jessica, Anagnostopoulos, Achiles, Anand, Sarah, Artz, Andrew, Aulitzky, Walter, Balderman, Sophia, Ballen, Karen, Becker, Michael, Beguin, Yves, Berkahn, Leanne, Berneman, Zwi, Bhatt, Vijaya, Bilmon, Ian, Bonifazi, Francesca, Briggs, Adrienne, Bruno, Benedetto, Brunstein, Claudio, Byrne, Michael, Byrne, Jenny, Cabrero, Monica, Cairoli, Roberto, Carrum, George, Cerny, Jan, Cheong, June-Won, Ciceri, Fabio, Colorado, Mercedes, Cook, Rachel, Couriel, Daniel, Craddock, Charles, Damon, Lloyd, Deol, Abhinav, Desbrosses, Yohan, Devine, Steve, Di Grazia, Carmela, Di Stasi, Antonio, Dias, Ajoy, Dorritie, Kathy, Essell, James, Eto, Tetsuya, Farag, Sherif, Forcade, Edouard, Frankfurt, Olga, Fujiwara, Shinichiro, Fukuda, Takahiro, Fukushima, Kentaro, Furst, Sabine, Goto, Tatsunori, Hall, Aric, Hatta, Shunsuke, Hicheri, Yosr, Horwitz, Mitchell, Hou, Hsin-An, How, Jonathan, Howard, Dianna, Hsu, Wei-Hsun (Blake), Huynh, Anne, Irvine, David, Ishikawa, Takayuki, Jamieson, Katarzyna, Jedrzejczak, Wieslaw, Jethava, Yogesh, Jimenez, Antonio, Jung, Chul Won, Kanda, Junya, Karakasis, Dimitrios, Kato, Jun, Kekre, Natasha, Khera, Nandita, Klein, Andreas, Kobbe, Guido, Kornblit, Brian, Kota, Vamsi, Lachance, Silvy, Leber, Brian, Lee, Catherine, Lee, Je Hwan, Lin, Tung-Liang, Liu, Ta-Chih, Martelli, Maurizio, Martinez, Carmen, Matsuoka, Kenichi, McCarty, John, Mendez, Lourdes, Michelis, Fotios, Mineishi, Shin, Mohty, Mohamad, Moors, Ine, Motyckova, Gabriela, Mueller, Lutz, Nakamae, Hirohisa, Nakano, Nobuaki, Nathan, Sunita, Nicholson, Emma, Norkin, Maxim, Ogawa, Yoshiaki, Olesen, Gitte, Oluwole, Olalekan, Pantin, Jeremy, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Piatkowska-Jakubas, Beata, Poire, Xavier, Protheroe, Rachel, Rambaldi, Alessandro, Ritchie, David, Ross, Kelly, Rubio, Marie-Therese, Santarone, Stella, Sanz Caballer, Jaime, Sawa, Masashi, Schaar, Dale, Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart, Shah, Nilay, Shah, Nirav, Shore, Tsiporah, Gil, Jorge Sierra, Singh, Anurag, Sobecks, Ronald, Socie, Gerard, Soiffer, Robert, Sprague, Kellie, Spyridonidis, Alexandros, Stelljes, Matthias, Stiff, Patrick, Stuart, Robert, Tanaka, Masatsugu, Tandra, Anand, Tholouli, Eleni, Thomas, Xavier, Tiribelli, Mario, Tomlinson, Benjamin, Tsirigotis, Panagiotis, Tzachanis, Dimitrios, Uchida, Naoyuki, Ueda, Masumi, Valcarcel Ferreiras, David, Wagner, Eva, Watson, Anne-Marie, Weisdorf, Daniel, Wolschke, Christine, Wrobel, Tomasz, Yakoub-Agha, Ibrahim, Yamauchi, Takuji, Yared, Jean, Yeh, Su-Peng, Yoon, Sung-Soo, Yoshihara, Satoshi, null, null, Levis, M, Hamadani, M, Logan, B, Jones, R, Singh, A, Litzow, M, Wingard, J, Papadopoulos, E, Perl, A, Soiffer, R, Ustun, C, Ueda Oshima, M, Uy, G, Waller, E, Vasu, S, Solh, M, Mishra, A, Muffly, L, Kim, H, Mikesch, J, Najima, Y, Onozawa, M, Thomson, K, Nagler, A, Wei, A, Marcucci, G, Geller, N, Hasabou, N, Delgado, D, Rosales, M, Hill, J, Gill, S, Nuthethi, R, King, D, Wittsack, H, Mendizabal, A, Devine, S, Horowitz, M, Chen, Y, Agura, E, Altman, J, Anagnostopoulos, A, Anand, S, Artz, A, Aulitzky, W, Balderman, S, Ballen, K, Becker, M, Beguin, Y, Berkahn, L, Berneman, Z, Bhatt, V, Bilmon, I, Bonifazi, F, Briggs, A, Bruno, B, Brunstein, C, Byrne, M, Byrne, J, Cabrero, M, Cairoli, R, Carrum, G, Cerny, J, Cheong, J, Ciceri, F, Colorado, M, Cook, R, Couriel, D, Craddock, C, Damon, L, Deol, A, Desbrosses, Y, Di Grazia, C, Di Stasi, A, Dias, A, Dorritie, K, Essell, J, Eto, T, Farag, S, Forcade, E, Frankfurt, O, Fujiwara, S, Fukuda, T, Fukushima, K, Furst, S, Goto, T, Hall, A, Hatta, S, Hicheri, Y, Horwitz, M, Hou, H, How, J, Howard, D, Hsu, W, Huynh, A, Irvine, D, Ishikawa, T, Jamieson, K, Jedrzejczak, W, Jethava, Y, Jimenez, A, Jung, C, Kanda, J, Karakasis, D, Kato, J, Kekre, N, Khera, N, Klein, A, Kobbe, G, Kornblit, B, Kota, V, Lachance, S, Leber, B, Lee, C, Lee, J, Lin, T, Liu, T, Martelli, M, Martinez, C, Matsuoka, K, Mccarty, J, Mendez, L, Michelis, F, Mineishi, S, Mohty, M, Moors, I, Motyckova, G, Mueller, L, Nakamae, H, Nakano, N, Nathan, S, Nicholson, E, Norkin, M, Ogawa, Y, Olesen, G, Oluwole, O, Pantin, J, Paulson, K, Pemberton, L, Perera, T, Piatkowska-Jakubas, B, Poire, X, Protheroe, R, Rambaldi, A, Ritchie, D, Ross, K, Rubio, M, Santarone, S, Sanz Caballer, J, Sawa, M, Schaar, D, Scheid, C, Schriber, J, Seropian, S, Shah, N, Shore, T, Gil, J, Sobecks, R, Socie, G, Sprague, K, Spyridonidis, A, Stelljes, M, Stiff, P, Stuart, R, Tanaka, M, Tandra, A, Tholouli, E, Thomas, X, Tiribelli, M, Tomlinson, B, Tsirigotis, P, Tzachanis, D, Uchida, N, Ueda, M, Valcarcel Ferreiras, D, Wagner, E, Watson, A, Weisdorf, D, Wolschke, C, Wrobel, T, Yakoub-Agha, I, Yamauchi, T, Yared, J, Yeh, S, Yoon, S, Yoshihara, S, Null, N, Levis, Mark J., Hamadani, Mehdi, Logan, Brent, Jones, Richard J., Singh, Anurag K., Litzow, Mark, Wingard, John R., Papadopoulos, Esperanza B., Perl, Alexander E., Soiffer, Robert J., Ustun, Celalettin, Ueda Oshima, Masumi, Uy, Geoffrey L., Waller, Edmund K., Vasu, Sumithra, Solh, Melhem, Mishra, Asmita, Muffly, Lori, Kim, Hee-Je, Mikesch, Jan-Henrik, Najima, Yuho, Onozawa, Masahiro, Thomson, Kirsty, Nagler, Arnon, Wei, Andrew H., Marcucci, Guido, Geller, Nancy L., Hasabou, Nahla, Delgado, David, Rosales, Matt, Hill, Jason, Gill, Stanley C., Nuthethi, Rishita, King, Denise, Wittsack, Heather, Mendizabal, Adam, Devine, Steven M., Horowitz, Mary M., Chen, Yi-Bin, Agura, Ed, Altman, Jessica, Anagnostopoulos, Achiles, Anand, Sarah, Artz, Andrew, Aulitzky, Walter, Balderman, Sophia, Ballen, Karen, Becker, Michael, Beguin, Yves, Berkahn, Leanne, Berneman, Zwi, Bhatt, Vijaya, Bilmon, Ian, Bonifazi, Francesca, Briggs, Adrienne, Bruno, Benedetto, Brunstein, Claudio, Byrne, Michael, Byrne, Jenny, Cabrero, Monica, Cairoli, Roberto, Carrum, George, Cerny, Jan, Cheong, June-Won, Ciceri, Fabio, Colorado, Mercedes, Cook, Rachel, Couriel, Daniel, Craddock, Charles, Damon, Lloyd, Deol, Abhinav, Desbrosses, Yohan, Devine, Steve, Di Grazia, Carmela, Di Stasi, Antonio, Dias, Ajoy, Dorritie, Kathy, Essell, James, Eto, Tetsuya, Farag, Sherif, Forcade, Edouard, Frankfurt, Olga, Fujiwara, Shinichiro, Fukuda, Takahiro, Fukushima, Kentaro, Furst, Sabine, Goto, Tatsunori, Hall, Aric, Hatta, Shunsuke, Hicheri, Yosr, Horwitz, Mitchell, Hou, Hsin-An, How, Jonathan, Howard, Dianna, Hsu, Wei-Hsun (Blake), Huynh, Anne, Irvine, David, Ishikawa, Takayuki, Jamieson, Katarzyna, Jedrzejczak, Wieslaw, Jethava, Yogesh, Jimenez, Antonio, Jung, Chul Won, Kanda, Junya, Karakasis, Dimitrios, Kato, Jun, Kekre, Natasha, Khera, Nandita, Klein, Andreas, Kobbe, Guido, Kornblit, Brian, Kota, Vamsi, Lachance, Silvy, Leber, Brian, Lee, Catherine, Lee, Je Hwan, Lin, Tung-Liang, Liu, Ta-Chih, Martelli, Maurizio, Martinez, Carmen, Matsuoka, Kenichi, McCarty, John, Mendez, Lourdes, Michelis, Fotios, Mineishi, Shin, Mohty, Mohamad, Moors, Ine, Motyckova, Gabriela, Mueller, Lutz, Nakamae, Hirohisa, Nakano, Nobuaki, Nathan, Sunita, Nicholson, Emma, Norkin, Maxim, Ogawa, Yoshiaki, Olesen, Gitte, Oluwole, Olalekan, Pantin, Jeremy, Paulson, Kristjan, Pemberton, Lucy, Perera, Travis, Piatkowska-Jakubas, Beata, Poire, Xavier, Protheroe, Rachel, Rambaldi, Alessandro, Ritchie, David, Ross, Kelly, Rubio, Marie-Therese, Santarone, Stella, Sanz Caballer, Jaime, Sawa, Masashi, Schaar, Dale, Scheid, Christoph, Schriber, Jeffrey, Seropian, Stuart, Shah, Nilay, Shah, Nirav, Shore, Tsiporah, Gil, Jorge Sierra, Singh, Anurag, Sobecks, Ronald, Socie, Gerard, Soiffer, Robert, Sprague, Kellie, Spyridonidis, Alexandros, Stelljes, Matthias, Stiff, Patrick, Stuart, Robert, Tanaka, Masatsugu, Tandra, Anand, Tholouli, Eleni, Thomas, Xavier, Tiribelli, Mario, Tomlinson, Benjamin, Tsirigotis, Panagiotis, Tzachanis, Dimitrios, Uchida, Naoyuki, Ueda, Masumi, Valcarcel Ferreiras, David, Wagner, Eva, Watson, Anne-Marie, Weisdorf, Daniel, Wolschke, Christine, Wrobel, Tomasz, Yakoub-Agha, Ibrahim, Yamauchi, Takuji, Yared, Jean, Yeh, Su-Peng, Yoon, Sung-Soo, Yoshihara, Satoshi, and null, null

Abstract

PURPOSEAllogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit.METHODSAdults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS.RESULTSThree hundred fifty-six participants were randomly assigned post-HCT to receive gilteritinib or placebo. Although RFS was higher in the gilteritinib arm, the difference was not statistically significant (hazard ratio [HR], 0.679 [95% CI, 0.459 to 1.005]; two-sided P =.0518). However, 50.5% of participants had MRD detectable pre- or post-HCT, and, in a prespecified subgroup analysis, gilteritinib was beneficial in this population (HR, 0.515 [95% CI, 0.316 to 0.838]; P =.0065). Those without detectable MRD showed no benefit (HR, 1.213 [95% CI, 0.616 to 2.387]; P =.575).CONCLUSIONAlthough the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.

Published
2024

21. Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Author

Chakraborty, Rajshekhar, Yi, Jean, Rybicki, Lisa, Preussler, Jaime, Deol, Abhinav, Loren, Alison, Savani, Bipin, Jim, Heather S.L., Cerny, Jan, Reynolds, Jana, Whitten, Jennifer, Wingard, John R., McGuirk, Joseph P., Uberti, Joseph, Khera, Nandita, Stiff, Patrick, Jaglowski, Samantha M., Hashmi, Shahrukh, Holtan, Shernan G., Devine, Steven, Hahn, Theresa, Whalen, Victoria L., Saber, Wael, Wood, William, Baker, K. Scott, Syrjala, Karen, and Majhail, Navneet S.

Published
2023
Full Text
View/download PDF

22. Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors

Author

Hong, Sanghee, Zhao, Jing, Wang, Shu, Wang, Han, Lee, Ji-Hyun, Farhadfar, Nosha, McGuirk, Joseph P., Savani, Bipin N., Shahrukh, Hashmi K., Stiff, Patrick, Khera, Nandita, Hahn, Theresa, Loren, Alison W., Jaglowski, Samantha M., Wood, William A., Saber, Wael, Cerny, Jan, Holtan, Shernan G., Reynolds, Jana M., Deol, Abhinav, Jim, Heather, Uberti, Joseph, Whalen, Victoria, Yi, Jean C., Preussler, Jaime, Baker, K. Scott, Shaw, Bronwen E., Devine, Steven, Syrjala, Karen, Majhail, Navneet S., Wingard, John R., and Al-Mansour, Zeina

Published
2023
Full Text
View/download PDF

23. Natural history of clonal haematopoiesis seen in real‐world haematology settings.

Author

Patel, Shyam A., Gerber, William K., Zheng, Rena, Khanna, Shrinkhala, Hutchinson, Lloyd, Abel, Gregory A., Cerny, Jan, DaSilva, Brandon A., Zhang, Tian Y., Ramanathan, Muthalagu, Khedr, Salwa, Selove, William, Woda, Bruce, Miron, Patricia M., Higgins, Anne W., and Gerber, Jonathan M.

Subjects
NATURAL history, HEMATOPOIESIS, DISEASE risk factors, RECURSIVE partitioning, HEMATOLOGY
Abstract

Summary: Recursive partitioning of healthy consortia led to the development of the Clonal Hematopoiesis Risk Score (CHRS) for clonal haematopoiesis (CH); however, in the practical setting, most cases of CH are diagnosed after patients present with cytopenias or related symptoms. To address this real‐world population, we characterize the clinical trajectories of 94 patients with CH and distinguish CH harbouring canonical DNMT3A/TET2/ASXL1 mutations alone ('sole DTA') versus all other groups ('non‐sole DTA'). TET2, rather than DNMT3A, was the most prevalent mutation in the real‐world setting. Sole DTA patients did not progress to myeloid neoplasm (MN) in the absence of acquisition of other mutations. Contrastingly, 14 (20.1%) of 67 non‐sole DTA patients progressed to MN. CHRS assessment showed a higher frequency of high‐risk CH in non‐sole DTA (vs. sole DTA) patients and in progressors (vs. non‐progressors). RUNX1 mutation conferred the strongest risk for progression to MN (odds ratio [OR] 10.27, 95% CI 2.00–52.69, p = 0.0053). The mean variant allele frequency across all genes was higher in progressors than in non‐progressors (36.9% ± 4.62% vs. 24.1% ± 1.67%, p = 0.0064). This analysis in the post‐CHRS era underscores the natural history of CH, providing insight into patterns of progression to MN. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Clonal Dynamics and Deterministic Clinical Fate Mapping of Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukemia with TP53 Disruption

Author

Patel, Shyam Ajay, primary, Tanenbaum, Benjamin, additional, Ediriwickrema, Asiri, additional, Cerny, Jan, additional, Hutchinson, Lloyd, additional, Meng, Xiuling, additional, Gerber, William K, additional, Khedr, Salwa, additional, Selove, William, additional, Woda, Bruce, additional, and Gerber, Jonathan M., additional

Published
2023
Full Text
View/download PDF

25. Post-transplantation cyclophosphamide is associated with increased bacterial infections

Author

Ustun, Celalettin, primary, Chen, Min, additional, Kim, Soyoung, additional, Auletta, Jeffery J., additional, Batista, Marjorie V., additional, Battiwalla, Minoo, additional, Cerny, Jan, additional, Gowda, Lohith, additional, Hill, Joshua A., additional, Liu, Hongtao, additional, Munshi, Pashna N., additional, Nathan, Sunita, additional, Seftel, Matthew D., additional, Wingard, John R., additional, Chemaly, Roy F., additional, Dandoy, Christopher E., additional, Perales, Miguel-Angel, additional, Riches, Marcie, additional, and Papanicolaou, Genovefa A., additional

Published
2023
Full Text
View/download PDF

26. Correction for Song et al., “Sustained Small Interfering RNA-Mediated Human Immunodeficiency Virus Type 1 Inhibition in Primary Macrophages”

Author

Song, Erwei, primary, Lee, Sang-Kyung, additional, Dykxhoorn, Derek M., additional, Novina, Carl, additional, Zhang, Dong, additional, Crawford, Keith, additional, Cerny, Jan, additional, Sharp, Phillip A., additional, Lieberman, Judy, additional, Manjunath, N., additional, and Shankar, Premlata, additional

Published
2023
Full Text
View/download PDF

27. Health-Related Quality of Life in Young Adult Survivors of Hematopoietic Cell Transplantation

Author

Rotz, Seth J., Yi, Jean C., Hamilton, Betty K., Wei, Wei, Preussler, Jaime M., Cerny, Jan, Deol, Abhinav, Jim, Heather, Khera, Nandita, Hahn, Theresa, Hashmi, Shahrukh K., Holtan, Shernan, Jaglowski, Samantha M., Loren, Alison W., McGuirk, Joseph, Reynolds, Jana, Saber, Wael, Savani, Bipin N., Stiff, Patrick, Uberti, Joseph, Wingard, John R., Wood, William A., Baker, K. Scott, Majhail, Navneet S., and Syrjala, Karen L.

Published
2022
Full Text
View/download PDF

28. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research

Author

Murthy, Hemant S., Ahn, Kwang Woo, Estrada-Merly, Noel, Alkhateeb, Hassan B., Bal, Susan, Kharfan-Dabaja, Mohamed A., Dholaria, Bhagirathbhai, Foss, Francine, Gowda, Lohith, Jagadeesh, Deepa, Sauter, Craig, Abid, Muhammad Bilal, Aljurf, Mahmoud, Awan, Farrukh T., Bacher, Ulrike, Badawy, Sherif M., Battiwalla, Minoo, Bredeson, Chris, Cerny, Jan, Chhabra, Saurabh, Deol, Abhinav, Diaz, Miguel Angel, Farhadfar, Nosha, Freytes, César, Gajewski, James, Gandhi, Manish J., Ganguly, Siddhartha, Grunwald, Michael R., Halter, Joerg, Hashmi, Shahrukh, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Jimenez-Jimenez, Antonio Martin, Kalaycio, Matt, Kamble, Rammurti, Krem, Maxwell M., Lazarus, Hillard M., Lazaryan, Aleksandr, Maakaron, Joseph, Munshi, Pashna N., Munker, Reinhold, Nazha, Aziz, Nishihori, Taiga, Oluwole, Olalekan O., Ortí, Guillermo, Pan, Dorothy C., Patel, Sagar S., Pawarode, Attaphol, Rizzieri, David, Saba, Nakhle S., Savani, Bipin, Seo, Sachiko, Ustun, Celalettin, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Wirk, Baldeep, Oran, Betul, Nakamura, Ryotaro, Scott, Bart, and Saber, Wael

Published
2022
Full Text
View/download PDF

29. Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions

Author

Patel, Shyam A., primary, Cerny, Jan, additional, Gerber, William K., additional, Ramanathan, Muthalagu, additional, Ediriwickrema, Asiri, additional, Tanenbaum, Benjamin, additional, Hutchinson, Lloyd, additional, Meng, Xiuling, additional, Flahive, Julie, additional, Barton, Bruce, additional, Gillis‐Smith, Andrew J., additional, Suzuki, Sakiko, additional, Khedr, Salwa, additional, Selove, William, additional, Higgins, Anne W., additional, Miron, Patricia M., additional, Simin, Karl, additional, Woda, Bruce, additional, and Gerber, Jonathan M., additional

Published
2023
Full Text
View/download PDF

32. The Mutational Landscape in Chronic Myelomonocytic Leukemia and Its Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for Blood and Marrow Transplantation Research (CIBMTR) Analysis

Author

Mei, Matthew, Pillai, Raju, Kim, Soyoung, Estrada-Merly, Noel, Afkhami, Michelle, Yang, Lixin, Meng, Zhuo, Abid, Muhammad Bilal, Aljurf, Mahmoud, Bacher, Ulrike, Beitinjaneh, Amer, Bredeson, Christopher, Cahn, Jean-Yves, Cerny, Jan, Copelan, Edward, Cutler, Corey, DeFilipp, Zachariah, Diaz Perez, Miguel Angel, Farhadfar, Nosha, Freytes, César O, Gadalla, Shahinaz M, Ganguly, Siddhartha, Gale, Robert Peter, Gergis, Usama, Grunwald, Michael R, Hamilton, Betty K, Hashmi, Shahrukh, Hildebrandt, Gerhard C, Lazarus, Hillard M, Litzow, Mark, Munker, Reinhold, Murthy, Hemant S, Nathan, Sunita, Nishihori, Taiga, Patel, Sagar S, Rizzieri, David, Seo, Sachiko, Shah, Mithun Vinod, Solh, Melhem, Verdonck, Leo F, Vij, Ravi, Sobecks, Ronald M, Oran, Betul, Scott, Bart L, Saber, Wael, Nakamura, Ryotaro, Mei, Matthew, Pillai, Raju, Kim, Soyoung, Estrada-Merly, Noel, Afkhami, Michelle, Yang, Lixin, Meng, Zhuo, Abid, Muhammad Bilal, Aljurf, Mahmoud, Bacher, Ulrike, Beitinjaneh, Amer, Bredeson, Christopher, Cahn, Jean-Yves, Cerny, Jan, Copelan, Edward, Cutler, Corey, DeFilipp, Zachariah, Diaz Perez, Miguel Angel, Farhadfar, Nosha, Freytes, César O, Gadalla, Shahinaz M, Ganguly, Siddhartha, Gale, Robert Peter, Gergis, Usama, Grunwald, Michael R, Hamilton, Betty K, Hashmi, Shahrukh, Hildebrandt, Gerhard C, Lazarus, Hillard M, Litzow, Mark, Munker, Reinhold, Murthy, Hemant S, Nathan, Sunita, Nishihori, Taiga, Patel, Sagar S, Rizzieri, David, Seo, Sachiko, Shah, Mithun Vinod, Solh, Melhem, Verdonck, Leo F, Vij, Ravi, Sobecks, Ronald M, Oran, Betul, Scott, Bart L, Saber, Wael, and Nakamura, Ryotaro

Abstract

Somatic mutations are recognized as an important prognostic factor in chronic myelomonocytic leukemia (CMML). However, limited data are available regarding their impact on outcomes after allogeneic hematopoietic cell transplantation (HCT). In this registry analysis conducted in collaboration with the Center for International Blood and Marrow Transplantation Registry database/sample repository, we identified 313 adult patients with CMML (median age: 64 years, range, 28- 77) who underwent allogeneic HCT during 2001-2017 and had an available biospecimen in the form of a peripheral blood sample obtained prior to the start of conditioning. In multivariate analysis, a CMML-specific prognostic scoring system (CPSS) score of intermediate-2 (HR=1.46, P=0.049) or high (HR=3.22, P=0.0004) correlated significantly with overall survival. When the molecularly informed CPSS-Mol prognostic model was applied, a high CPSS-Mol score (HR=2 P=0.0079) correlated significantly with overall survival. The most common somatic mutations were in ASXL1 (62%), TET2 (35%), KRAS/NRAS (33% combined), and SRSF2 (31%). DNMT3A and TP53 mutations were associated with decreased overall survival (HR=1.70 [95% CI: 1.11-2.60], P=0.0147 and HR=2.72 [95% CI: 1.37-5.39], P=0.0042, respectively) while DNMT3A, JAK2, and TP53 mutations were associated with decreased disease-free survival (HR=1.66 [95% CI: 1.11-2.49], P=0.0138, HR=1.79 [95% CI: 1.06-3.03], P=0.0293, and HR=2.94 [95% CI: 1.50-5.79], P=0.0018, respectively). The only mutation associated with increased relapse was TP53 (HR=2.94, P=0.0201). Nonetheless, the impact of TP53 mutations specifically should be interpreted cautiously given their rarity in CMML. We calculated the goodness of fit measured by Harrell's C-index for both the CPSS and CPSS-Mol, which were very similar. In summary, via registry data we have determined the mutational landscape in patients with CMML who underwent allogeneic HCT, and demonstrated an association between CPSS-Mol and t

Published
2023

33. Supplementary Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report

Author

Kim, Haesook T., primary, Ahn, Kwang Woo, primary, Hu, Zhen-Huan, primary, Davids, Matthew S., primary, Volpe, Virginia O., primary, Antin, Joseph H., primary, Sorror, Mohamed L., primary, Shadman, Mazyar, primary, Press, Oliver, primary, Pidala, Joseph, primary, Hogan, William, primary, Negrin, Robert, primary, Devine, Steven, primary, Uberti, Joseph, primary, Agura, Edward, primary, Nash, Richard, primary, Mehta, Jayesh, primary, McGuirk, Joseph, primary, Forman, Stephen, primary, Langston, Amelia, primary, Giralt, Sergio A., primary, Perales, Miguel-Angel, primary, Battiwalla, Minoo, primary, Hale, Gregory A., primary, Gale, Robert Peter, primary, Marks, David I., primary, Hamadani, Mehdi, primary, Ganguly, Sid, primary, Bacher, Ulrike, primary, Lazarus, Hillard, primary, Reshef, Ran, primary, Hildebrandt, Gerhard C., primary, Inamoto, Yoshihiro, primary, Cahn, Jean-Yves, primary, Solh, Melhem, primary, Kharfan-Dabaja, Mohamed A., primary, Ghosh, Nilanjan, primary, Saad, Ayman, primary, Aljurf, Mahmoud, primary, Schouten, Harry C., primary, Hill, Brian T., primary, Pawarode, Attaphol, primary, Kindwall-Keller, Tamila, primary, Saba, Nakhle, primary, Copelan, Edward A., primary, Nathan, Sunita, primary, Beitinjaneh, Amer, primary, Savani, Bipin N., primary, Cerny, Jan, primary, Grunwald, Michael R., primary, Yared, Jean, primary, Wirk, Baldeep M., primary, Nishihori, Taiga, primary, Chhabra, Saurabh, primary, Olsson, Richard F., primary, Bashey, Asad, primary, Gergis, Usama, primary, Popat, Uday, primary, Sobecks, Ronald, primary, Alyea, Edwin, primary, Saber, Wael, primary, and Brown, Jennifer R., primary

Published
2023
Full Text
View/download PDF

34. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis

Author

Murthy, Guru Subramanian Guru, primary, Kim, Soyoung, additional, Estrada-Merly, Noel, additional, Abid, Muhammad Bilal, additional, Aljurf, Mahmoud, additional, Assal, Amer, additional, Badar, Talha, additional, Badawy, Sherif M., additional, Ballen, Karen, additional, Beitinjaneh, Amer, additional, Cerny, Jan, additional, Chhabra, Saurabh, additional, DeFilipp, Zachariah, additional, Dholaria, Bhagirathbhai, additional, Perez, Miguel Angel Diaz, additional, Farhan, Shatha, additional, Freytes, Cesar O., additional, Gale, Robert Peter, additional, Ganguly, Siddhartha, additional, Gupta, Vikas, additional, Grunwald, Michael R., additional, Hamad, Nada, additional, Hildebrandt, Gerhard C., additional, Inamoto, Yoshihiro, additional, Jain, Tania, additional, Jamy, Omer, additional, Juckett, Mark, additional, Kalaycio, Matt, additional, Krem, Maxwell M., additional, Lazarus, Hillard M, additional, Litzow, Mark, additional, Munker, Reinhold, additional, Murthy, Hemant S., additional, Nathan, Sunita, additional, Nishihori, Taiga, additional, Ortí, Guillermo, additional, Patel, Sagar S., additional, Van der Poel, Marjolein, additional, Rizzieri, David A., additional, Savani, Bipin N, additional, Seo, Sachiko, additional, Solh, Melhem, additional, Verdonck, Leo F., additional, Wirk, Baldeep, additional, Yared, Jean A., additional, Nakamura, Ryotaro, additional, Oran, Betul, additional, Scott, Bart, additional, and Saber, Wael, additional

Published
2023
Full Text
View/download PDF

35. Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation (AHCT) for Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL): Secondary Analysis from Two Multicenter Randomized Controlled Trials (RCT) of Hematopoietic Cell Transplant Survivorship Interventions

Author

Mian, Agrima, primary, Wei, Wei, additional, Chakraborty, Rajshekhar, additional, Yi, Jean, additional, Preussler, Jaime M., additional, Hill, Brian T., additional, Cerny, Jan, additional, Deol, Abhinav, additional, Hahn, Theresa E., additional, Hashmi, Shahrukh K., additional, Jaglowski, Samantha, additional, Jim, Heather S.L., additional, Khera, Nandita, additional, Loren, Alison W., additional, McGuirk, Joseph P., additional, Savani, Bipin, additional, Stiff, Patrick, additional, Uberti, Joseph, additional, Whalen, Victoria, additional, Wingard, John R, additional, Reynolds, Jana, additional, Holtan, Shernan Grace, additional, Wood, William Allen A., additional, Baker, Scott, additional, Syrjala, Karen L., additional, Hamilton, Betty K., additional, and Majhail, Navneet S., additional

Published
2023
Full Text
View/download PDF

37. Prognostic Discrimination within a Heterogeneous Population of TP53-Aberrant Myelodysplastic Syndromes and Acute Myeloid Leukemia

Author

Patel, Shyam A, primary, Cerny, Jan, additional, Gerber, William K, additional, Gillis-Smith, Andrew, additional, Ramanathan, Muthalagu, additional, Suzuki, Sakiko, additional, Hutchinson, Lloyd, additional, Higgins, Anne, additional, Miron, Patricia Minehart, additional, Horgan, Ryan, additional, Milano, Andrea, additional, Perron, Christie, additional, Pransky, Rachel, additional, Shanahan, Lindsey, additional, Simin, Karl, additional, Tonelli, Alyssa, additional, and Gerber, Jonathan M, additional

Published
2022
Full Text
View/download PDF

38. Impaired Clearance of DNMT3A/TET2/ASXL1-Mutant Clones with Hypomethylating Agent or Intensive Induction Chemotherapy for Myelodysplastic Syndrome and Acute Myeloid Leukemia

Author

Patel, Shyam A, primary, Gerber, William K, additional, Hutchinson, Lloyd, additional, Cerny, Jan, additional, Ramanathan, Muthalagu, additional, Gillis-Smith, Andrew, additional, Suzuki, Sakiko, additional, Khedr, Salwa, additional, Woda, Bruce, additional, Selove, William, additional, and Gerber, Jonathan M, additional

Published
2022
Full Text
View/download PDF

39. Natural History of Patients with Clonal Hematopoiesis Seen in Hematology Clinics

Author

Patel, Shyam A, primary, Gerber, William K, additional, Hutchinson, Lloyd, additional, Khanna, Shrinkhala, additional, Cerny, Jan, additional, Ramanathan, Muthalagu, additional, Gillis-Smith, Andrew, additional, Suzuki, Sakiko, additional, Abel, Gregory A., additional, Khedr, Salwa, additional, Selove, William, additional, Woda, Bruce, additional, Zheng, Rena, additional, Miron, Patricia Minehart, additional, Higgins, Anne, additional, and Gerber, Jonathan M, additional

Published
2022
Full Text
View/download PDF

40. Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions

Author

Mian, Agrima, primary, Wei, Wei, additional, Chakraborty, Rajshekhar, additional, Yi, Jean C., additional, Preussler, Jaime M., additional, Hill, Brian T., additional, Cerny, Jan, additional, Deol, Abhinav, additional, Hahn, Theresa E., additional, Hashmi, Shahrukh K., additional, Jaglowski, Samantha, additional, Jim, Heather S.L., additional, Khera, Nandita, additional, Loren, Alison W., additional, McGuirk, Joseph P., additional, Savani, Bipin N., additional, Stiff, Patrick, additional, Uberti, Joseph P., additional, Whalen, Victoria, additional, Wingard, John R., additional, Reynolds, Jana, additional, Holtan, Shernan G, additional, Wood, William A., additional, Baker, K. Scott, additional, Syrjala, Karen L., additional, Hamilton, Betty K., additional, and Majhail, Navneet S., additional

Published
2022
Full Text
View/download PDF

41. Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors

Author

Hong, Sanghee, primary, Zhao, Jing, additional, Wang, Shu, additional, Wang, Han, additional, Lee, Ji-Hyun, additional, Farhadfar, Nosha, additional, McGuirk, Joseph P., additional, Savani, Bipin N., additional, Shahrukh, Hashmi K., additional, Stiff, Patrick, additional, Khera, Nandita, additional, Hahn, Theresa, additional, Loren, Alison W., additional, Jaglowski, Samantha M., additional, Wood, William A., additional, Saber, Wael, additional, Cerny, Jan, additional, Holtan, Shernan G., additional, Reynolds, Jana M., additional, Deol, Abhinav, additional, Jim, Heather, additional, Uberti, Joseph, additional, Whalen, Victoria, additional, Yi, Jean C., additional, Preussler, Jaime, additional, Baker, K. Scott, additional, Shaw, Bronwen E., additional, Devine, Steven, additional, Syrjala, Karen, additional, Majhail, Navneet S., additional, Wingard, John R., additional, and Al-Mansour, Zeina, additional

Published
2022
Full Text
View/download PDF

42. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients

Author

Boyiadzis, Michael, primary, Zhang, Mei-Jie, additional, Chen, Karen, additional, Abdel-Azim, Hisham, additional, Abid, Muhammad Bilal, additional, Aljurf, Mahmoud, additional, Bacher, Ulrike, additional, Badar, Talha, additional, Badawy, Sherif M., additional, Battiwalla, Minoo, additional, Bejanyan, Nelli, additional, Bhatt, Vijaya Raj, additional, Brown, Valerie I., additional, Castillo, Paul, additional, Cerny, Jan, additional, Copelan, Edward A., additional, Craddock, Charles, additional, Dholaria, Bhagirathbhai, additional, Perez, Miguel Angel Diaz, additional, Ebens, Christen L., additional, Gale, Robert Peter, additional, Ganguly, Siddhartha, additional, Gowda, Lohith, additional, Grunwald, Michael R., additional, Hashmi, Shahrukh, additional, Hildebrandt, Gerhard C., additional, Iqbal, Madiha, additional, Jamy, Omer, additional, Kharfan-Dabaja, Mohamed A., additional, Khera, Nandita, additional, Lazarus, Hillard M., additional, Lin, Richard, additional, Modi, Dipenkumar, additional, Nathan, Sunita, additional, Nishihori, Taiga, additional, Patel, Sagar S., additional, Pawarode, Attaphol, additional, Sharma, Akshay, additional, Solh, Melhem, additional, Wagner, John L., additional, Wang, Trent, additional, Williams, Kirsten M., additional, Winestone, Lena E., additional, Wirk, Baldeep, additional, Hourigan, Christopher S., additional, Litzow, Mark, additional, Kebriaei, Partow, additional, de Lima, Marcos, additional, Page, Kristin, additional, and Weisdorf, Daniel J., additional

Published
2022
Full Text
View/download PDF

47. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Author

Wieduwilt, Matthew J., Metheny, Leland, Zhang, Mei-Jie, Wang, Hai-Lin, Estrada-Merly, Noel, Marks, David, I, Al-Homsi, A. Samer, Muffly, Lori, Chao, Nelson, Rizzieri, David, Gale, Robert Peter, Gadalla, Shahinaz M., Cairo, Mitchell, Mussetti, Alberto, Gore, Steven, Bhatt, Vijaya Raj, Patel, Sagar S., Michelis, Fotios, V, Inamoto, Yoshihiro, Badawy, Sherif M., Copelan, Edward, Palmisiano, Neil, Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Ganguly, Siddhartha, Bredeson, Christopher, Diaz Perez, Miguel Angel, Cassaday, Ryan, Savani, Bipin N., Ballen, Karen, Martino, Rodrigo, Wirk, Baldeep, Bacher, Ulrike, Aljurf, Mahmoud, Bashey, Asad, Murthy, Hemant S., Yared, Jean A., Aldoss, Ibrahim, Farhadfar, Nosha, Liu, Hongtao, Abdel-Azim, Hisham, Waller, Edmund K., Solh, Melhem, Seftel, Matthew D., van der Poel, Marjolein, Grunwald, Michael R., Liesveld, Jane L., Kamble, Rammurti T., McGuirk, Joseph, Munker, Reinhold, Cahn, Jean-Yves, Lee, Jong Wook, Freytes, Cesar O., Krem, Maxwell M., Winestone, Lena E., Gergis, Usama, Nathan, Sunita, Olsson, Richard F., Verdonck, Leo F., Sharma, Akshay, Ringden, Olle, Friend, Brian D., Cerny, Jan, Choe, Hannah, Chhabra, Saurabh, Nishihori, Taiga, Seo, Sachiko, George, Biju, Baxter-Lowe, Lee Ann, Hildebrandt, Gerhard C., de Lima, Marcos, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Abid, Muhammad Bilal, Weisdorf, Daniel J., Saber, Wael, Wieduwilt, Matthew J., Metheny, Leland, Zhang, Mei-Jie, Wang, Hai-Lin, Estrada-Merly, Noel, Marks, David, I, Al-Homsi, A. Samer, Muffly, Lori, Chao, Nelson, Rizzieri, David, Gale, Robert Peter, Gadalla, Shahinaz M., Cairo, Mitchell, Mussetti, Alberto, Gore, Steven, Bhatt, Vijaya Raj, Patel, Sagar S., Michelis, Fotios, V, Inamoto, Yoshihiro, Badawy, Sherif M., Copelan, Edward, Palmisiano, Neil, Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Ganguly, Siddhartha, Bredeson, Christopher, Diaz Perez, Miguel Angel, Cassaday, Ryan, Savani, Bipin N., Ballen, Karen, Martino, Rodrigo, Wirk, Baldeep, Bacher, Ulrike, Aljurf, Mahmoud, Bashey, Asad, Murthy, Hemant S., Yared, Jean A., Aldoss, Ibrahim, Farhadfar, Nosha, Liu, Hongtao, Abdel-Azim, Hisham, Waller, Edmund K., Solh, Melhem, Seftel, Matthew D., van der Poel, Marjolein, Grunwald, Michael R., Liesveld, Jane L., Kamble, Rammurti T., McGuirk, Joseph, Munker, Reinhold, Cahn, Jean-Yves, Lee, Jong Wook, Freytes, Cesar O., Krem, Maxwell M., Winestone, Lena E., Gergis, Usama, Nathan, Sunita, Olsson, Richard F., Verdonck, Leo F., Sharma, Akshay, Ringden, Olle, Friend, Brian D., Cerny, Jan, Choe, Hannah, Chhabra, Saurabh, Nishihori, Taiga, Seo, Sachiko, George, Biju, Baxter-Lowe, Lee Ann, Hildebrandt, Gerhard C., de Lima, Marcos, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Abid, Muhammad Bilal, Weisdorf, Daniel J., and Saber, Wael

Abstract

The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLAmatched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P <_ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P <_ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (<_18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.

Published
2022
Full Text
View/download PDF

48. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis

Author

Mei, Matthew, primary, Pillai, Raju, additional, Kim, Soyoung, additional, Estrada-Merly, Noel, additional, Afkhami, Michelle, additional, Yang, Lixin, additional, Meng, Zhuo, additional, Abid, Muhammad Bilal, additional, Aljurf, Mahmoud, additional, Bacher, Ulrike, additional, Beitinjaneh, Amer, additional, Bredeson, Christopher, additional, Cahn, Jean-Yves, additional, Cerny, Jan, additional, Copelan, Edward, additional, Cutler, Corey, additional, DeFilipp, Zachariah, additional, Diaz Perez, Miguel Angel, additional, Farhadfar, Nosha, additional, Freytes, César O., additional, Gadalla, Shahinaz M., additional, Ganguly, Siddhartha, additional, Gale, Robert Peter, additional, Gergis, Usama, additional, Grunwald, Michael R., additional, Hamilton, Betty K., additional, Hashmi, Shahrukh, additional, Hildebrandt, Gerhard C., additional, Lazarus, Hillard M., additional, Litzow, Mark, additional, Munker, Reinhold, additional, Murthy, Hemant S., additional, Nathan, Sunita, additional, Nishihori, Taiga, additional, Patel, Sagar S., additional, Rizzieri, David, additional, Seo, Sachiko, additional, Shah, Mithun Vinod, additional, Solh, Melhem, additional, Verdonck, Leo F., additional, Vij, Ravi, additional, Sobecks, Ronald M., additional, Oran, Betul, additional, Scott, Bart L., additional, Saber, Wael, additional, and Nakamura, Ryotaro, additional

Published
2022
Full Text
View/download PDF

50. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors

Author

Guru Murthy, Guru Subramanian, primary, Kim, Soyoung, additional, Hu, Zhen-Huan, additional, Estrada-Merly, Noel, additional, Abid, Muhammad Bilal, additional, Aljurf, Mahmoud, additional, Bacher, Ulrike, additional, Badawy, Sherif M., additional, Beitinjaneh, Amer, additional, Bredeson, Chris, additional, Cahn, Jean-Yves, additional, Cerny, Jan, additional, Diaz Perez, Miguel Angel, additional, Farhadfar, Nosha, additional, Gale, Robert Peter, additional, Ganguly, Siddhartha, additional, Gergis, Usama, additional, Hildebrandt, Gerhard C., additional, Grunwald, Michael R., additional, Hashmi, Shahrukh, additional, Hossain, Nasheed M., additional, Kalaycio, Matt, additional, Kamble, Rammurti T., additional, Kharfan-Dabaja, Mohamed A., additional, Hamilton, Betty Ky, additional, Lazarus, Hillard M., additional, Liesveld, Jane, additional, Litzow, Mark, additional, Marks, David I., additional, Murthy, Hemant S., additional, Nathan, Sunita, additional, Nazha, Aziz, additional, Nishihori, Taiga, additional, Patel, Sagar S., additional, Pawarode, Attaphol, additional, Rizzieri, David, additional, Savani, Bipin, additional, Seo, Sachiko, additional, Solh, Melhem, additional, Ustun, Celalettin, additional, van der Poel, Marjolein, additional, Verdonck, Leo F., additional, Vij, Ravi, additional, Wirk, Baldeep, additional, Oran, Betul, additional, Nakamura, Ryotaro, additional, Scott, Bart, additional, and Saber, Wael, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results